OurView Health Review
Best for: Budget shoppers wanting low-cost compounded GLP-1 via a membership savings model
OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications. Weight loss is compounded semaglutide (from $75) and tirzepatide (from $135), shipped in 30-day supplies; it also covers TRT/HRT, women's BHRT, and wellness peptides. Medications are compounded by an unnamed licensed third-party pharmacy. A full legal suite is published; the site claims LegitScript Approval, not independently verified here.
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
OurView Health is one of the most affordable GLP-1 options on the market.
OurView Health at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $75/mo
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How we scored OurView Health
Each dimension is scored algorithmically from OurView Health’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
8.8/10At $75/mo, OurView Health runs about 56% below the $169 median for GLP-1 providers.
Effectiveness25%
7.8/10OurView Health offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.1/10Online intake and platform experience — consult included in the price; 8 platform features disclosed.
Trust & Safety15%
7.0/10Core details confirmed by our editors; no FDA warning letters on file (last checked 2026-06-22).
Accessibility10%
5.8/10OurView Health's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
5.6/10OurView Health provides standard clinician follow-up; no extended coaching or community program is disclosed.
How we verified this OurView Health review
Last checked 2026-06-22- Confirmed current pricing across 2 dose/plan tiers
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
GLP-1 medications OurView Health offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
Ready to get started?
Plans and promotions change often — check OurView Health's current pricing and active discounts before you decide.
What we like
- Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
- Clear product pricing with no contracts; medication shipped to your door (30-day supply)
- Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
- Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)
Watch-outs
- 'Starting at' prices likely require Savings Club membership and/or a longer plan
- Compounding pharmacy partner not named ('licensed third-party pharmacy')
- 'LegitScript Approved' is stated on the site but was not independently verified here
- Operating medical entity not clearly named (site operated by a marketing agency)
Is OurView Health worth it? Our verdict
OurView Health positions itself around one thing: Budget shoppers wanting low-cost compounded GLP-1 via a membership savings model. It runs $75/month — toward the affordable end of the market.
How much OurView Health actually costs
- Compounded semaglutide — $75/month
- Compounded tirzepatide — $135/month
That puts OurView Health below the roughly $169 median ongoing price across the GLP-1 providers we track — a real cost advantage.
Medications: what OurView Health prescribes
OurView Health prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two molecules with the strongest published weight-loss trial outcomes. These are dispensed as compounded formulations from a licensed pharmacy, which is how the price stays below brand-name pens. Compounded drugs aren't FDA-approved as finished products — the standard trade-off across the compounded-GLP-1 market.
Who OurView Health is best for — and who should skip it
A good fit if you…
- are focused on the lowest ongoing monthly cost.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
OurView Health earns its place on the shortlist mainly on price: at $75/month it's one of the more affordable ways to stay on a GLP-1, without obvious corners cut on access or oversight.
Ready to start with OurView Health?
Starting at $75/month. See current pricing and start your free consultation.
Alternatives to OurView Health
Editorial score · methodology
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this OurView Health review:
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Ready to start with OurView Health?
Starting at $75/month. See current pricing and start your free consultation.